Skip to content

Study · Systematic review · n = 73,640 · 2025

3 results

Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.

Natividade GR, Spiazzi BF, Baumgarten MW, Bassotto C, Pereira AA, Fraga BL, Scalco BG, Mattes NR, Lavinsky D, Kramer CK, Gerchman F

JAMA ophthalmology1 Sept 2025Cited by 26 (Europe PMC)

PMID40810985 (opens in a new tab)PMCIDPMC12355393 (opens in a new tab)DOI10.1001/jamaophthalmol.2025.2489 (opens in a new tab)PepBankPUB-40810985
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in adults, semaglutide did not increase or reduce the risk of eye disorders (OR 1.01; 95% CI 0.91-1.12).

    In plain wordsIn adults in pooled trials, semaglutide did not raise or lower the risk of eye disorders compared with placebo or another drug.

    Peptide
    Semaglutide
    Outcome
    No significant changeEye disorders
    Study

    n = 73,640

    Comparator
    Placebo or active comparator
    Analysis
    Primary
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    OR
    1.01 ratio
    eye disorders

    Source sentences

    Summary
    Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17).
    2 context sentences
    Summary · context
    Investigators independently screened records to identify randomized clinical trials comparing semaglutide with either an active comparator or placebo in adults, assessing ocular adverse events.
    Summary · context
    A total of 78 trials with 73 640 participants were included.
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in adults, semaglutide did not increase or reduce the risk of diabetic retinopathy (OR 1.04; 95% CI 0.92-1.17).

    In plain wordsIn adults in pooled trials, semaglutide did not raise or lower the risk of diabetic retinopathy compared with placebo or another drug.

    Peptide
    Semaglutide
    Outcome
    No significant changeDiabetic retinopathy
    Study

    n = 73,640

    Comparator
    Placebo or active comparator
    Analysis
    Primary
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    OR
    1.04 ratio
    diabetic retinopathy

    Source sentences

    Summary
    Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17).
    2 context sentences
    Summary · context
    Investigators independently screened records to identify randomized clinical trials comparing semaglutide with either an active comparator or placebo in adults, assessing ocular adverse events.
    Summary · context
    A total of 78 trials with 73 640 participants were included.
  3. 03HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in adults, semaglutide was associated with significantly higher odds of NAION (OR 3.92; 95% CI 1.02-15.02).

    In plain wordsIn adults in pooled trials, semaglutide was linked to higher odds of a rare optic nerve problem called NAION, but the evidence is not firm.

    Peptide
    Semaglutide
    Outcome
    IncreaseNonarteritic anterior ischemic optic neuropathy (NAION)
    Study

    n: not reported in source

    Comparator
    Placebo or active comparator
    Analysis
    Primary
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    OR
    3.92 ratio
    NAION

    Source sentences

    Summary
    Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02).
    2 context sentences
    Summary · context
    Investigators independently screened records to identify randomized clinical trials comparing semaglutide with either an active comparator or placebo in adults, assessing ocular adverse events.
    Summary · context
    A total of 78 trials with 73 640 participants were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.